This study is being done to test the effectiveness and safety of an investigational medication called SAR442970 compared to placebo in participants with moderate to severe ulcerative colitis (UC) who either have not responded to prior treatment or were unable to tolerate prior treatments.

The purpose of the CHROMA-CD study is to find out if SAR442970 is safe and effective in improving the symptoms of CD. 

The primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy.

The primary objective of this research is to evaluate specific and non-specific effects of hypnotherapy. 

The secondary objective is to evaluate the efficacy of group-format gut-directed hypnotherapy delivered via telehealth for managing gastrointestinal health.

Phase IIa, Single-arm, Open-label, Multi-center Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Induction and Subcutaneous Maintenance Treatment With BI 3032950 in Patients With Moderate to Severe Ulcerative Colitis

This study is testing a medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn’s Disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.

This study is testing an investigational medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn's disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.

This study is testing an investigational medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat ulcerative colitis (UC). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating UC.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is. This is compared to a placebo in people living with moderately to severely active UC.

This study is testing an investigational medicine called afimkibart.  Afimkibart is an investigational medicine being developed to treat ulcerative colitis (UC)  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active UC.

The study objective is to assess the efficacy, safety, and pharmacokinetics of an investigational drug in pediatric subjects from 2 to < 18 years of age with moderately to severely active Crohn’s disease (CD) who have had inadequate responses, loss of response, or intolerance to corticosteroids, immunosuppressants, and/or biologics, or in whom use of those therapies is medically contraindicated.